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Placental Function: Historical View
The intimate connection between the fetus and placenta has been recognized throughout history, but understanding of placental function has undergone many shifts. In early ancient Egypt, for example, the placenta was invested with extraordinary power as the alter ego or twin of the infant. (1) Thus, the recognition of the king as a living god led to the remarkable development of the Cult of the Royal Placenta. The Pharaoh's placenta was retained and protected throughout his life; it was the symbol that led the royal standard on the earliest known royal Egyptian inscriptions. At death, it was ritually cut open and likely buried with him to proceed into the afterlife. Despite such reverence, there is no indication that a function for the placenta was recognized beyond general "protection" of the fetus. Later, Hellenistic philosophers recognized the nutritive function of the placenta, believing that the fetal and maternal circulations were in direct contact and that the fetus was partially nourished by it, either through the umbilical cord or by suckling on the placenta. (1) This understanding persisted into the Renaissance. Leonardo da Vinci depicted this intimate connection between fetus, placenta, and uterus ( Fig. 1) , although he depicted not the discoidal human placenta but rather the cotyledonous (multilobular) cow placenta.
By the late 1500s, the concept of the placenta as a blood "purifier" developed. More importantly, the separation of fetal and maternal circulation was recognized. This observation, based on dissection, was confirmed a mere 200 years later by injection of the fetal circulation with colored wax. (2) Separate circulations led to problems with the nutritive theory because there was no concept of transmembrane transport at the time, so interest instead turned to the potential respiratory function of the placenta, with the identification of oxygen (also known as "pure air" or "ether") and its transport by blood. Erasmus Darwin (Charles Darwin's grandfather and best known for authoring Zoonomia, his opus on physiology (2)) described this new concept in the most poetic terms:
"Thus in the womb the nascent infant laves Its natant form in the circumfluent waves; With perforated heart unbreathing swims, Awakes and stretches all its recent limbs; With gills placental seeks the arterial flood, And drinks pure ether from its Mother's blood."-Canto I, The Temple of Nature, 1803
Placental Function: Modern View
The placenta now is understood to be the first fetal organ that becomes functional during pregnancy, an organ that plays an essential role in both fetal development and maternal health. As the interface between maternal and fetal circulation, the placenta monitors maternal wellbeing and nutritional status and aims to modify this environment to optimize fetal well-being through changes in placental function. Placental substrate transport, metabolism, protection of the fetus, and hormone production all are critical to fetal well-being.
Over the past 2 decades, placental functions largely have been investigated in relation to fetal growth, due to rising interest in "fetal programming" or "Barker's hypothesis," the concept that impaired intrauterine growth results in long-term reprogramming of endocrine function in the fetus, leading to adult coronary artery disease, hypertension, and diabetes. Considerable effort has been expended on unraveling placental mechanisms that change fetal growth and lead to "reprogramming." Excellent recent reviews on this topic are available. (3)(4) Perhaps because poor fetal growth due to nutrition or hypoxia tends to be "brain-sparing," at least for a while, the link between placental function and brain development has been discussed far less. In addition, the fetus often is considered to develop in a "protected" environment, buffered from maternal and placental hormones. However, many examples call this view into question, including thyroid hormone transferred from maternal circulation that is needed for neuronal proliferation, (5) maternal and placental steroids that change the fetal hypothalamic-pituitary-adrenal axis, (6) and peptide hormones such as oxytocin for which there is growing evidence of direct impact on fetal brain development. (7)(8) Figure 1 . Leonardo da Vinci's studies on the human fetus and placenta. Detailed anatomic drawings of the placenta are rare until the late 16th century. To the left, da Vinci depicts a human fetus surrounded by a placenta that has multiple connections with the surrounding uterus. To the right are more detailed drawings of the anatomy of these cotyledons, as would be seen in cow placenta (to which he likely had much more ready access).
Many of the developmental disorders of childhood, such as cerebral palsy (CP), cognitive impairment from prematurity, and autism, appear to result from an interaction of complex genetic traits and environmental factors. Similarly, adult psychiatric diseases may have their origins in impaired early, even fetal, development, as proposed for schizophrenia. (9) Despite major efforts, these prevalent, debilitating, lifelong disorders remain biologically unexplained. The intimate connection between mother, fetus, and placenta and the vast array of active neurohormones expressed in the placenta make the placenta a prime target when investigating fetal environmental disruptions that can affect the brain.
The evidence that links placental hormone dysfunction to changes in brain development is intriguing but largely circumstantial. Animal data pointing toward this hypothesis show that in utero loss of several placentally provided neuropeptides significantly changes dendritic development and animal behavior. (8)(10) Human epidemiology studies provide evidence that even late preterm infants who generally are not ill (born between 32 and 37 weeks' gestation and comprising most preterm births) still are at significantly increased risk of later cognitive dysfunction, possibly due to early placental loss. Sex differences in neurologic outcome, with males having a much higher incidence of prematurity-related damage and autism, suggest an impact of sex steroids but do not distinguish between placenta and fetal steroid production. Studies more specifically linking placental function to neurologic outcome, including the massive National Collaborative Perinatal Project (NCPP), which prospectively followed more than 50,000 pregnancies, focused on the macro-and microscopic anatomy of the placenta rather than placental dysfunction or loss. The NCPP and many other studies were designed to test whether oxygen deprivation at birth caused CP, a chronic cortical motor deficit, and showed that fewer than 15% of cases can be linked to delivery room hypoxia, suggesting that prior fetal events or placental malfunctions are to blame. Focus in the field now is on inflammation caused by uterine infection as a possible source of damage causing both CP and preterm birth, but there are not yet any definitive studies linking placental inflammation with structural brain pathology in humans. Remarkably, some evidence links structural placental anomalies, such as abnormal rests of cells (inclusion cysts) more commonly seen in multisystem genetic syndromes, to conditions involving isolated cognitive deficits, such as autism. (11) Finally, recent work suggests a direct link between prematurity and autism, possibly due to placental hormone loss. (12) None of these human studies, however, directly links changes in placental hormones with neurologic impairment.
In this article, we explore the potential link between hormones and brain development by reviewing placental transport and metabolic and protective functions and by directly exploring placental endocrinology in relation to fetal brain development. We complete the review with an examination of new methods that may define and clarify the relationship of placental function to normal brain development and possibly to neurodevelopmental pathologies such as autism.
Transport, Metabolism, and Protection
The details of placental structure needed for nutrient and gas transport have been reviewed many times at the . Provided by Stanford Univ Med Ctr on February 4, 2010 http://neoreviews.aappublications.org Downloaded from structural level and are noted only briefly here. The human placenta is a disc-shaped organ covered in specialized cells that make direct contact with maternal blood (Fig. 2) . (13) Substances moving from mother to fetus or vice versa cross multiple highly specialized tissue layers: syncytiotrophoblast, cytotrophoblast, villous basement membrane, and the fetal capillary bed (Fig. 2) . This enormous exchange surface grows from 5 m 2 at 28 weeks' gestation to approximately 12 m 2 at term. Such intricate, extensive maternal-fetal contact allows the placenta to perform its best-described functions: transport, metabolism, and protection of the fetus ( Fig. 3; Tables 1, 2, and 3 ).
Gases such as oxygen and carbon dioxide diffuse across the placental layers in response to differences in partial pressure. In addition, the placenta has multiple facilitated and active transport mechanisms (Table 1) . Facilitated diffusion transfers critical nutrients, such as glucose. Large quantities of glucose are moved via hexose transporters (GLUT3 and GLUT1). Amino acids are moved by active transport against their concentration gradient from maternal to fetal circulation, concentrating them in the fetus for optimal growth. In addition to intact transport, many nutrients are metabolized in the placenta (Table 2 ). For example, fetal energy production relies heavily on lactate, which is metabolized from glucose in the placenta prior to reaching the fetal circulation. The fetus also needs a high concentration of glycine, much of which may be metabolized from serine that is readily taken up by the placenta from maternal supplies.
In addition to moving substances from mother to fetus and back again, the placenta acts as a protective barrier against multiple potential insults: destruction by the maternal immune system, bacterial or viral maternal infections, and exposure to many toxic substances or drugs ( Table 3 ). The placenta expresses export pumps to decrease placental passage of toxins. Degradative enzymes reduce passage of many polypeptides and some steroids. Large molecules (molecular weight Ͼ500 kDa) are less likely to cross the placenta, and proteins are more likely to be digested, but exceptions exist. Relatively large molecules can cross this barrier, including beneficial ones such as thyroid hormone and maternal immunoglobulin G and detrimental ones such as thalidomide and other teratogens. Because the specific rules that govern molecular passage are only known in outline, drugs and hormones need to be tested individually to determine their placental transfer, a daunting but necessary task needed for better understanding of the physiologic communication between mother, placenta, and fetus. New molecular methods, discussed at the end of this review, may increase the rate of progress in identifying transporter expression, metabolic pathways in the placenta, and compounds present in fetal or cord blood.
The Endocrine Placenta
In addition to its role in transporting molecules between mother and fetus, the placenta is a major endocrine organ capable of secreting a plethora of hormones as well as transferring others from the maternal circulation (Table 4) . (14)(15) Placental hormones are made almost exclusively in the syncytiotrophoblasts. The diverse hormones produced have major influences on both fetal and maternal physiology, including the brain. Placental hormones act as regulators of fetal growth and development for the benefit of the fetus. Their effects may be endocrine, paracrine, or autocrine. Three major types of placental hormones have been described:
• Hormones produced by the mother that act on the placenta and can pass to the fetus in an active (possibly modified) form: thyroid hormone, prolactin, oxytocin, progestins, estrogens
• Hormones produced by the fetus, modified in the placenta, and passed to the fetus or the mother: dehydroepiandrosterone (DHEA)
• Hormones produced by the placenta and passed to mother, fetus, or both: chorionic gonadotrophin (hCG) to maternal circulation, placental lactogen (hPL) to maternal and fetal circulation, placental growth hormone (pGH) to maternal circulation, corticotropinreleasing hormone (CRH) to maternal and fetal circulation, insulin-like growth factor-2 (IGF2) to fetal circulation Some of these are exclusively placental hormones that are not produced by other organs but have known functions during pregnancy. Included in this category are members of the growth hormone (GH)-prolactin (PRL) gene family. (16) Placental members of the GH-PRL gene family, for example, are exclusive to the placenta and appear to modulate maternal and fetal metabolism, luteal function, and mammogenesis.
More commonly, hormones initially manufactured in the fetal placenta are manufactured later in other fetal endocrine organs, particularly in the fetal brain. Besides modulation of the brain, placental hormones can modulate maternal brain circuitry and behavior in preparation for parturition and rearing of offspring. (17) Indeed, given the extensive shared expression of hormones in the brain and placenta and the communication between them, it seems fair to call the placenta the first fetal "neuroendocrine organ." 
Placental Neuroendocrine Hormones
There are two major classes of neuroendocrine hormones: steroid and peptide hormones, both of which are made by the placenta. They may have direct or indirect effects on the developing fetal brain. There are many examples of potential effects on the developing brain. We highlight hormones in each category to illustrate the general principles of communication from placenta to developing fetal brain.
Steroid Hormones
Placental synthesis and secretion of estrogens and progestins increase throughout pregnancy. Steroid hormones are highly lipophilic and cross the placenta in both directions. The placenta is an "incomplete" steroidogenic organ and does not express a complete set of enzymes for de novo production of estrogens and progesterone. Steroid hormone synthesis in the placenta is dependent on precursors from mother and fetus, leading to the concept of an integrated maternal-fetal-placental unit (Fig. 4A) . Via this unit, circulating steroids frequently are transformed into their derivatives, changing their neuroactive potential as they are processed in the placenta (Fig. 4B) .
One of the best examples of the neuroactive hormones made by the maternal-fetal-placental unit is placental progestins. By week 10 of gestation, the placental syncytiotrophoblast captures low-density and very lowdensity lipoproteins from maternal circulation and converts this maternal substrate into pregnenolone and then into progesterone. This placental progesterone maintains the pregnancy, relaxing the gravid uterus and inhibiting fetal rejection by suppression of maternal lymphocyte activity. (18) Placental progestins enter both maternal and fetal circulation, crossing the blood-brain barrier to promote both maternal and fetal neurogenesis. Progesterone and other steroids exert their effects in the brain through a variety of mechanisms. The classic mechanism of activation involves steroid binding to specific nuclear receptors, creating active transcription factors that bind to DNA to change gene expression and, thus, cell behavior. Nongenomic, rapid signaling mech- anisms for progesterone also have been identified and appear to be present in the developing brain. (21) It is likely that most progesterone in fetal brain tissue is placental in origin, but it also can be synthesized de novo in the developing brain from placental steroid precursors. (22) Neural sensitivity to progesterone made in either the brain or the placenta can be conferred by the pattern of nuclear progesterone receptors expressed in specific brain regions as well as the expression of secondary signaling pathways in developing neurons. In the fetal hypothalamus, sexual dimorphism in progesterone receptor expression may be both a cause and effect of the sex steroid milieu, (23) suggesting that progesterone exposure may have previously unrecognized effects on sexually dimorphic traits.
Progesterone also can be derivatized into the highly active neurosteroid allopregnanolone (Fig.  4B) . (22) This two-step enzymatic process occurs in the fetal brain and also may occur in the late-gestation placenta. Allopregnanolone, which reaches peak concentrations in fetal brain in late gestation, modulates neural excitability through gammaaminobutyric acid (GABA A ) receptors (much like a benzodiazepine or barbiturate). The concentrations of allopregnanolone in the fetal brain increase in response to parturition, stress, and hypoxia, suggesting that it can play a role in protecting the developing brain from excitotoxic cell death. (24)
Placental dysfunction or complete loss of the placenta due to preterm birth removes the primary source of progesterone and the precursors to allopregnanolone, potentially disrupting normal developmental patterns that require progesterone signaling and leaving the developing brain susceptible to excitotoxic damage. Use of exogenous progestins to maintain a high-risk pregnancy, particularly natural progestins that can cross the placenta and blood-brain barrier, also may have unintended consequences for fetal brain development and deserves further investigation. (23) Another important derivative of placental progesterone is glucocorticoid. Glucocorticoids are not placental products per se, but they are intimately connected to placental hormone function and brain development, particularly the function of the hypothalamic-pituitaryadrenal (HPA) axis and maturation of the hippocampus. (25) In the fetus, placental progesterone is converted into glucocorticoids in the fetal adrenals (Fig. 4A) . The role of the placenta is to limit fetal exposure to maternal glucocorticoids. The placenta partially inactivates maternal cortisol via 11-beta-hydroxisteroid dehydrogenase type 2 (11-beta-HSD2), which converts active cortisol to inactive cortisone. The fetal brain is protected further by high concentrations of 11-beta-HDS2 expressed in the fetal brain until the end of the second trimester. (25) In some species (eg, guinea pig), the end of pregnancy is marked by decreased 11-beta-HDS2 placental expression and subsequent exposure to increased cortisol. In human pregnancies, fetal glucocorticoid exposure frequently results from the administration of synthetic glucocorticoids to promote lung maturation in anticipated preterm birth. Despite the protective effects of synthetic glucocorticoids against the neurologic complications of prematurity (intraventricular hemorrhage and periventricular leukomalacia), excess administration and perhaps the choice of synthetic steroid (dexamethasone versus betamethasone) can result in decreased central nervous system (CNS) growth and reprogramming of the HPA axis, predisposing offspring to hypertension and poor stress regulation. (25) Glucocorticoids are an example of maternal hormones that can affect fetal brain development either directly, when they cross the placenta, or indirectly by changing the expression and secretion of other placental hormones. For example, maternal glucocorticoids can stimulate placental CRH and adrenocorticotropic hormone production, resulting in additional activation of the fetal HPA axis. (26) The physiologic response of the HPA axis as well as the susceptibility of other brain regions to glucocorticoid-induced damage depends on the timing of these insults. For example, developing hippocampal neurons may be injured (or at least have an increased susceptibility to injury) by cortisol or hippocampal maturation may be sped up, potentially changing later hippocampal learning or memory function. (27) Taken together, it is becoming clear that placental progesterone and its derivatives can play a critical, complex role in the development of the fetal brain.
Peptide Hormones
Nonsteroid hormones transported or manufactured by the placenta long have been thought not to cross into the fetal compartment. However, evidence is growing that the fetus is exposed to several neuroactive peptide hormones.
For many years, it was believed that maternal thyroid hormones such as thyroxine (molecular weight, 776 kDa) could not enter fetal circulation to have a direct effect on fetal development. However, it is now well recognized that maternal thyroxine does transfer and is important for neurogenesis and long-term cognitive development, particularly in the first trimester of pregnancy; even subclinical hypothyroidism in the mother is associated with neurodevelopmental delay in the child. (5) After the first trimester, thyroxine still can enter fetal circulation, as demonstrated by 40% to 60% of normal thyroid hormone concentrations in athyrotic newborns. The success of thyroid replacement therapy started after birth for athyroid children in preventing cognitive sequelae, despite the brain's need for thyroid hormone throughout gestation, also points to this placental transfer. The placenta maintains tight control of this transfer using plasma membrane transporters, binding of thyroxine by trophoblastic cell proteins, and hormone inactivation by placental enzymes.
Oxytocin is produced in the syncytiotrophoblasts, and concentrations increase during pregnancy in parallel with maternal circulating serum concentrations. Concentrations in the placenta are several times higher than in the maternal pituitary gland, suggesting that the placenta may be a critical oxytocin source during pregnancy. (28) The role of oxytocin in fetal neurodevelopment is far more speculative than that of thyroid hormone, but evidence from both animal and human studies suggest transfer across or from the placenta and entry across the immature blood-brain barrier. (8)(29) Like allopregnanolone, oxytocin shifts GABA signaling from excitatory to inhibitory, again providing a mechanism to protect the fetal brain from excess excitation that can lead to cell death. A remarkable recent study in mice suggested that maternal oxytocin enters the fetal CNS just prior to delivery to protect the fetal brain from damage associated with potential hypoxia or stress during this event. (8) In addition, oxytocin concentrations have been linked to social behavior, and oxytocin pathway signaling may be impaired in social disorders such as autism. (30) In humans, a direct link between fetal oxytocin exposure and autism has not yet been demonstrated. Potential effects of oxytocin passage to the fetus should be considered since the agent so often is used to augment labor. One hypothesis is that oxytocin may downregulate fetal oxytocin receptor concentrations, contributing to the development of autism in susceptible children. (29) However, the mouse study suggests rather that oxytocin should be neuroprotective during labor. Both animal experiments and human epidemiology studies are needed to clarify the role of oxytocin in fetal brain development and later social functioning.
As seen in Table 4 , many other protein hormones are expressed in the placenta. In addition, more may be transferred from the maternal circulation that might affect the development of the fetal brain. Some have been used as markers for healthy placentation, fetal growth, and predictors of preterm birth (CRH, IGF2, hCG), but they are not well explored as neuroactive hormones, in large part because it has been assumed that they cannot cross the placenta. In light of the more recent findings from thyroxine and oxytocin placental passage or production, it seems worth re-exploring their effects under normal and pathologic circumstances using modern molecular tools.
Placental Cytokines
One final category of signaling molecules made by the placenta is worth noting: cytokines (Table 5) . Cytokines are small secreted proteins that initially were defined as immune modulators but now are known to mediate nonimmune functions as well. For example, in the developing brain, cytokines act as neuronal chemoattractants during migration and axon extension and later as modulators of neuronal connectivity, survival, and loss. In the past decade, the link between cytokines and normal and abnormal CNS development has become a major area of investigation in neuroscience. (31) Although cytokines generally have local affects, they can signal as hormones over long distances, such as when the placenta responds to maternal infection or inflammation with cytokine production that interacts with normal neurodevelopmental processes. Epidemiologic studies suggest a link between prenatal immune activation with cytokine production and neurodevelopmental disorders as diverse as CP and schizophrenia. (32) Animal experiments further suggest that dysregulation of specific cytokines or their downstream signaling pathways can have long-term CNS structural and behavioral effects. (31) The precise neurologic impact of inflammatory (eg, interleukin-6) and anti-inflammatory (eg, interleukin-10) cytokines released by the placenta deserves extensive investigation because of the large number of pregnancies in which infections may compromise placental function transiently or provoke preterm delivery. Maternal infection is not the only cause of placental cytokine changes; preeclamptic pregnancies have disrupted cytokine balance, with increased production of tumor necrosis factoralpha, interleukin-1, interleukin-8, and interferon-gamma. 
Modern Tools for Investigation of the Endocrine Placenta
Progress in the field of placental biology has been relatively slow due to the inability of the mammalian embryo to develop without the placenta and the placenta being a complex, transient organ that is difficult to manipulate without completely disrupting pregnancy. Disregard for the value of placental analysis, with most human placentae ending up discarded in a bucket on the delivery room floor, plus a lack of modern tools and strategies to investigate placental-fetal developmental has hindered the field. Traditional investigations using primarily histologic and descriptive methods have been the primary tools. This pattern is beginning to change as sophisticated molecular analysis is applied to the human placenta and molecular manipulation is used to investigate placental function directly in animal models.
Models of Placental Function Human Placenta
The most compelling approach to understanding the human placenta is to study it directly. However, access generally is limited to postpartum tissue. In addition, analysis is complicated by the range of genetic backgrounds in both mother and fetus, mixed conditions such as infection and preeclampsia, and limited samples from the second trimester of gestation (when there are few terminations and few previability deliveries in genetically normal pregnancies).
Two basic approaches have been taken to this problem: acute studies of human placenta and establishment of cell cultures. Several ex vivo perfusion systems have been established to study the acute transport and metabolic functions of human placentas. These systems have the advantage of yielding information about human hormone exchange across the placenta at the end of pregnancy, but they are limited in terms of experiment duration and replication of complex in utero function. Acute placental samples also can give a "snapshot" of the gene or protein expressed at the end of a pregnancy but cannot reveal the time course of development. To understand the time course of placental hormone expression and secretion, at least in a dish, human cell lines derived either from early placental trophoblast or human choriocarcinoma have been established. (35) Most recently, human (36) Unlike the fields of cancer biology or neurodegeneration, which have extensive tissue banking programs that collect tumor samples or brains for future research, placental tissue, which is far easier to obtain, has been banked only sporadically. Developing a national resource for placental tissue research would significantly speed progress in understanding human placental function.
Animal Models
There is no perfect animal model to understand the function of the human placenta. Even primates have some striking variations in placental structure. However, despite considerable morphologic differences, genetic control and physiologic function are relatively well conserved in the mammalian placenta. (37)(38) The mouse, rat, guinea pig, sheep, and nonhuman primates are the most common models, each with its unique set of advantages and disadvantages (Table 6 ).
New Methods to Interrogate Placental Function and Dysfunction
Many of the new high-throughput molecular techniques for evaluating genetic and epigenetic patterns across multiple samples have begun to be applied to the placenta. Detailed explanation of each method is beyond the scope of this review, but the basic principles as they relate to placental studies are illustrated in Figure 5 . The time course of normal gene expression patterns across gestation has been examined in human and mouse placenta using genome-wide gene expression arrays. (39)(40) Although the sample sets generally have been small, the genetic program that underlies the ongoing changes in the developing trophoblasts, which is remarkable for an abrupt shift in overall gene expression pattern in midgestation, is strikingly similar between mouse and human. (39)(40) However, more than 50% of the individual genes expressed may be species-specific. (39)(41) Changes in gene expression patterns, gene polymorphisms, and epigenetic marks that may be linked to common placental diseases, such as preeclampsia, are starting to be explored (Fig. 5A) . (42)(43)(44) The epigenetic regulation of placental function is likely to be particularly intriguing because despite sharing the same genetic makeup as the fetus, the placenta has a very different set of epigenetic marks that likely control functions specific to the placenta and regulate fetal wellbeing. (44) These types of analyses may yield identification of hormones expressed by the placenta that were not recognized previously. Using bioinformatics approaches, testable predictions can be made about complex networks of placental enzymes or other regulatory net- 
Direct Genetic Manipulation of the Placenta
The advantage to the new types of analyses previously described is that they are very likely to yield new hypotheses about placental function and dysfunction. Many of these correlations then can be tested directly in mice. Until very recently, tools to probe gene function specifically in the placenta or to rescue placental phenotypes that cause embryonic lethality were limited, even in mice. Transgenic mice are the modern tool that usually is used to manipulate gene expression and subsequent protein production. Conditional gene expression controlled by site-specific recombinase systems expressed in specific tissue patterns are revealing precise gene functions, (45) but only a few of these tools exist for the placenta. (46) The primary method available for placental manipulation has been tetraploid complementation, an arduous technique in which chimeras are generated by aggregating tetraploid embryos with mutant diploid embryos or with diploid embryonic stem cells carrying a mutation of interest. This method can work for placental studies focused on distinguishing lethality due to placental versus fetal gene mutation because the tetraploid cells generally are excluded from the derivatives of the inner cell mass (ie, the fetus). (47) However, the variable mosaicism that results in placenta generated using this method significantly complicates interpretation. On the other hand, attempts to generate transgenic placenta from viral injection has been hampered by inefficient infection rates as well as damage and mosaicism associated with direct injection. (48)(49) Such limitations highlight the need to develop novel methods for analyzing placental effects on fetal neurodevelopment.
In exciting new developments, lentiviruses have been used to transfer modified genes to the fetus and generate transgenic mice. Lentiviral infection of the embryo at the earliest morula stages results in fully transgenic offspring. (50)(51) In contrast, lentiviral infection at the later blastocyst stage of embryogenesis allows for effi- (Fig. 5B) . (50)(51) The efficient and prolonged expression of inserted transgenes in the placenta make this a far superior technique to any available in the past. This technique now brings the power of high-throughput molecular studies and the possibility of gain-and loss-of-function analyses of genes specifically to the placenta, opening the door to innovative strategies to test the impact of placental gene and protein expression on many aspects of pregnancy, including fetal brain development.
The Future: A Deeper Understanding of Placental Impact on Fetal Development
Demonstrating that specific placental hormones shape neurologic diseases could fundamentally shift current research and treatment much in the same way that the Barker hypothesis, which proposed that fetal undernutrition sets up long-term risk for adult systemic disease such as heart disease, changed our view of coronary risk factors and, more broadly, of lifelong programming of disease. Barker's epidemiologic discovery that individuals who developed coronary heart disease grew differently in utero has led to the recognition of new developmental models for the disease and new approaches to nutrition. Similarly, if disruption of oxytocin function in utero or sudden loss of placental progesterone following preterm birth can be shown to cause neurologic damage, we need to focus on when and how such disruptions first arise and how to ameliorate them. Redefining CP, prematurity-related cognitive disabilities, autism, or even adult mental disorders such as schizophrenia as diseases that can be "programmed" by placental signals that fundamentally and permanently change the way the brain is wired opens the door to a paradigm shift in the way we think about these disorders.
